Navigation Links
SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Date:8/7/2008

. is a biotechnology company focused on the discovery, development and commercialization of novel, targeted therapeutics directed at addressing unmet medical needs in oncology. Our drug development programs target the MET receptor tyrosine kinase, an enzyme implicated in a broad array of cancers, and the BCR-ABL tyrosine kinase enzyme for the treatment of Chronic Myelogenous Leukemia, or CML. Our drug discovery activities are focused on a portfolio of other protein and enzyme targets that have been implicated in human cancers, including JAK2, RON, ALK, RAS and IKKe. More information on the pipeline and drug discovery platform can be found at http://www.sgxpharma.com and in the Company's various filings with the Securities and Exchange Commission.

Merger Agreement with Eli Lilly and Company

On July 8, 2008, SGX Pharmaceuticals, Inc. entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation ("Lilly"), and REM Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Lilly ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub will merge with and into SGX (the "Merger"), with SGX continuing as the surviving corporation and a wholly-owned subsidiary of Lilly. As a result of the Merger, each share of SGX common stock issued and outstanding immediately prior to the effective time of the Merger (other than shares held by Lilly or Merger Sub or by stockholders of SGX who have validly exercised their appraisal rights under Delaware law) will be converted into the right to receive $3.00 in cash, without interest.

Pursuant to the terms of the Merger Agreement and as permitted under the applicable SGX equity plans, all of SGX's unvested stock options will vest prior to the effective time of the Merger. Any issued and outstanding stock options with an exercise price per share greater than or equal to $3.00 that are not exe
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
9. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
10. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
11. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 Unraveling life’s mysteries can intrigue, ... Archer Family purchased a DNA test to ... up with a lifetime of memories, sharing, and closeness. ... members’ DNA genuinely brought the family closer together. ... into genetic history and prior to taking the ...
(Date:7/10/2014)... 2014 EvoDerma ’s NOOME Anti-Aging Motion ... device now comes with a second treatment cup to help ... The new cup is thinner on the edges for a ... rough, thin and uneven surfaces on the face, neck and ... stimulating treatment on areas such as the cheeks and neck, ...
(Date:7/10/2014)... , July 10, 2014 ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique ... MabNext project BIOCAD develops a number of innovative drugs ... autoimmune diseases. The ceremony took place at the International ...
(Date:7/10/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/s3bqj2/photonic ) has ... Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... traces its roots in the latter half of ... went unexplored and unfulfilled for several decades owing ...
Breaking Biology Technology:Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2
... the Harvard Business Review (HBR), containing an ... , questioned the impact of IT investments. This has ... One of the dissenters of Carrs article is PRISM ... specializes in Outsourced Marketing Services and uses technology to ...
... eFilm to offer an integrated PAC (picture achieving and ... target market of hospitals and imaging centers. , ... milestone in our evolution as a healthcare software and ... our target market," said Rich Linden, Merge eFilm president ...
... Ill. Though electricity and telephones dont even exist at ... the next highly underserved segment to be wired by ... Monday. Motorola says Indian reservations could be the most ... ,When identifying the need for high-speed Internet access for ...
Cached Biology Technology:IT Does Matter! 2IT Does Matter! 3Merge eFilm to buy Ohio firm in $14M Deal 2Merge eFilm to buy Ohio firm in $14M Deal 3Motorola Canopy Wires Indian Reservations 2
(Date:7/11/2014)... Researchers have pioneered a revolutionary new way to ... Virtual Finger, allows scientists to move through digital ... using the flat surface of their computer screens. ... orders of magnitude more efficient, saving time, money ... areas of experimental biology. The software and its ...
(Date:7/11/2014)... to the hippocampus, the marginal division of the ... What is the impact degree of substance P ... memory function? Yan Yu and his team, College ... using immunofluorescence staining, that substance P receptor, neurokinin ... striatal marginal division of normal rats. Unilateral or ...
(Date:7/11/2014)... 11, 2014 Research and Markets ... Technology Market - Industry Analysis Size Share Growth Trends ... http://photos.prnewswire.com/prnh/20130307/600769 ... created a need for high level security in both ... authentication such as username and passwords, tokens etc. are ...
Breaking Biology News(10 mins):Virtual finger enables scientists to navigate and analyze complex 3D images 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
... 8, 2011 When expressed (turned on), the ... the enzyme telomerase. Human cells can keep living ... i.e. the cells become immortal . Telomerase ... extend human cell life indefinitely. TA-65®  is a ...
... , NARRAGANSETT, RI -- June 7, 2011 -- Sunshine Menezes, ... Reporting, and 2010 Grantham Prize winner Alanna Mitchell announced the ... on the Environment. James Astill of The Economist will receive ... Them," a commanding 8-part special report on the state of ...
... only organisms that turn to caffeine for a pick-me-up. University ... can live on caffeine. One of them, known as ... outside a UI research laboratory. The research team says the ... works -- could in the future allow scientists to convert ...
Cached Biology News:A Molecule That Turns on the Immortality Gene! 2A Molecule That Turns on the Immortality Gene! 3$75,000 Grantham Prize winner announced 2$75,000 Grantham Prize winner announced 3University of Iowa researchers identify caffeine-consuming bacterium 2
Monoclonal Mouse Anti-Human Cytokeratin 16 (48 kD)...
Sheep polyclonal to Melatonin ( Abpromise for all tested applications). Antigen: Melatonin Tg conjugate....
Rabbit polyclonal to NCoR2, prediluted ( Abpromise for all tested applications). entrezGeneID: 9612 SwissProtID: Q9Y618...
Rabbit polyclonal to TRPM8 (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 79054 SwissProtID: Q3YFM7...
Biology Products: